Tg Therapeutics Inc stock is traded at $57.98, with a volume of 2,110,818. It is down -5.92% in the last 24 hours and up +7.55% over the past month. TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Previous Close:
$61.63
Open:
$61.50
24h Volume:
2,110,818
Relative Volume:
1.10
Market Cap:
$8.87B
Revenue:
$700.35M
Net Income/Loss:
$461.90M
P/E Ratio:
20.20
EPS:
$2.87
Net Cash Flow:
-$14.19M
1W Performance:
-0.17%
1M Performance:
+7.55%
6M Performance:
+60.61%
1Y Performance:
+70.33%
1-Day Range:
$57.82$61.59
1-Week Range:
$57.82$63.60
52-Week Range:
$26.76$63.60
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(212) 554-4484Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS